- Available in pharmacies, Mallya is compatible with most
disposable insulin pens1
- Patients have a digital solution to accurately2 and safely
monitor their day-to-day treatment
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible
PEA PME) , a French company specialized in the design,
development and manufacturing of innovative medical devices, and
Roche Diabetes Care France, a reference company in the support of
patients with diabetes, announce the launch in France of Mallya, a
medical device available in pharmacies. Developed by BIOCORP, this
smart insulin pen device collects and transfers insulin data with
near 100% accuracy2. Rechargeable via its USB port, Mallya is
compatible with most disposable insulin pens1. This innovation aims
to simplify the daily life of patients with diabetes undergoing
insulin therapy, and could help avoid errors or oversights.
Healthcare companies BIOCORP and Roche Diabetes Care France are
finalizing their collaboration - announced last June - with the
distribution of Mallya smart devices for insulin injection pens
since the beginning of April. Manufactured in Clermont-Ferrand
(France), this innovation for patients taking insulin is the first
in its category to receive the CE-mark (medical device).
Reusable and compatible with 91%1 of disposable insulin pens,
Mallya automatically collects insulin data (dose, date, time) and
transfers it to the Gluci-Chek application developed by Roche
Diabetes Care France, ensuring qualified information on which the
patient can rely and the physician can then make decisions3. With
integration into the Roche Diabetes Care France digital ecosystem,
patients benefit from solutions that lighten the mental burden of
their disease, in a context where more than 750,000 people4 are
treated with insulin injections in France (excluding insulin
pumps).
“The commercial launch of Mallya represents an important
milestone for BIOCORP. We are really proud to be leading it with
Roche Diabetes Care France. Its leading position, its vast
distribution network in pharmacies and the connection of our
innovative device to its Gluci-Chek solution present undeniable
benefits for all healthcare professionals but also and above all
for diabetic patients looking for a better quality of life, a
better comfort in the management and daily follow-up of their
disease", said Eric Dessertenne, CEO of BIOCORP.
"For more than 40 years, we have been helping people with
diabetes think less about the day-to-day management of their
disease. We are committed to the autonomy and quality of life of
patients with diabetes, empowering them to understand and act on
their condition. This is precisely what Mallya allows, when
integrated with our digital ecosystem for patients and healthcare
professionals. We are currently the only company to offer a quality
solution based on a CE marked medical device", added Frédéric
Jacquey, President of Roche Diabetes Care France.
An innovation to improve the daily life and monitoring of
diabetic patients on insulin
After the creation of insulin for therapeutic purposes 100 years
ago, innovation continues in the field of diabetes, with the same
ambition: to enable more and more patients to live better with
their diabetes on a daily basis, a strong challenge for patients
treated with insulin. To this end, Mallya collects and transfers
insulin data in real time5 to their smartphone.
Once the device is installed, the patient selects and injects
his or her insulin units as usual, with data transfer (date, time,
selected dose) being done automatically. While 37%6 of patients
with diabetes felt more anxious about their condition during the
first Covid19 confinement, the simple and accurate2 Mallya device
makes it easier for them to follow the evolution of their disease.
It could thus contribute to more serenity, more security and less
error or forgetfulness in taking their treatment.
Shared with healthcare professionals3 through the dedicated
Roche Diabetes Care Platform, accurate and comprehensive insulin
data2 allows them to monitor - face-to-face or remotely - the
progress of their patients' disease, refine their interpretation
and help adjust treatment decisions.
A device integrated into a global solution to facilitate
diabetes management
The device enhances Roche Diabetes Care France's digital
ecosystem for integrated personalized diabetes management. This
solution was previously based on three elements: connected blood
glucose meters (Accu-Chek® Mobile, Accu-Chek® Guide), the
Gluci-Chek application and the Roche Diabetes Care platform
dedicated to healthcare professionals. Mallya is adding insulin
data for more comprehensive patient monitoring.
Used regularly by more than 60,000 diabetic patients in France,
this smartphone application combines three major functionalities
for personalized diabetes management: a carbohydrate calculation
tool with a visualization of the portions on the plate, a
self-monitoring of blood glucose diary and a graphic visualization
of glycemic results.
Once Mallya is connected to Gluci-Chek, the patient no longer
has to manually report his or her insulin doses, as the data is
automatically displayed in the patient's blood glucose logbook, for
any compatible insulin pen1. In a context where French people are
confined again and where 58%3 of patients with diabetes did not
feel they had received any particular help during their first
confinement, this connected device can provide real close
monitoring.
ABOUT ROCHE DIABETES CARE FRANCE
Roche Diabetes Care is a healthcare company specializing in
diabetes. For more than 40 years, it has been pioneering solutions
to meet the needs of patients and healthcare professionals: medical
devices (blood glucose meters, auto-pickers, insulin pumps),
digital solutions (applications, platform for sharing blood glucose
data between patients and healthcare professionals) and services
(information and therapeutic education support). Through the
implementation of a global solution connecting medical devices and
digital solutions, Roche Diabetes Care is paving the way for
integrated Personalized Diabetes Management (iPDM), with the aim of
facilitating and optimizing the management and monitoring of this
complex disease.
Roche Diabetes Care France is a subsidiary of the Roche Group in
France, alongside Roche SAS France and Roche Diagnostics France.
For more information, please visit www.roche.fr.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture
of medical devices and delivery systems, BIOCORP has today acquired
a leading position in the connected medical device market thanks to
Mallya. This smart sensor for insulin injection pens allows
reliable monitoring of injected doses and thus offers better
compliance in the treatment of patients with diabetes. Available
for sale from 2020, Mallya spearheads BIOCORP's product portfolio
of innovative connected solutions. The company has 70 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 –
ALCOR). For more information, please visit www.biocorpsys.com.
1 The Mallya medical device is compatible with Solostar pens
(ref. 9828648001), FlexPen pens (ref. 9832360001) and KwikPen pens
(ref. 9827587001) with the exception of Junior KwikPen pens as of
January 1, 2021. Calculation of market share for disposable insulin
pens from Caisse Nationale d'Assurance Maladie. Open Medic 2019
database.
2 99% according to Mallya IFU version 6. Caution: some external
factors may affect the accuracy of dose measurement or data
transfer.
3 If the patient decides to share his/her data.
4 Source: IQVIA - LTD : Analysis of BGMin real life – Meters and
strips markets - CMA February 2020 - Patients and volume.
5 As soon as Bluetooth is activated.
6 Online study conducted by CSA Research for Roche Diabetes Care
France from May 18th to 27th, 2020, with 504 diabetic patients (101
type1 diabetic patients and 403 type2 diabetic patients)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210412005837/en/
BIOCORP Jacques Gardette
Chairman of the Board investisseurs@biocorp.fr Éric Dessertenne
Chief Executive Officer Sylvaine Dessard Marketing &
Communication Director rp@biocorp.fr + 33 (0)6 88 69 72 85
ULYSSE COMMUNICATION Bruno
Arabian barabian@ulysse-communication.com +33 (0)6 87 88 46 26
Nicolas Daniels ndaniels@ulysse-communication.com +33 (0)6 63 66 59
22 ROCHE DIABETES CARE FRANCE
Myriam Hamza rochediabpresse@havas.com +33 (0)6 45 87 46 51
Nathalie Neyroz nathalie.neyroz@roche.com +33 (0)7 78 38 09 12
Biocorp (EU:ALCOR)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biocorp (EU:ALCOR)
Historical Stock Chart
Von Apr 2023 bis Apr 2024